{"id":75308,"date":"2026-08-19T12:19:58","date_gmt":"2026-08-19T04:19:58","guid":{"rendered":"https:\/\/flcube.com\/?p=75308"},"modified":"2026-08-19T12:19:59","modified_gmt":"2026-08-19T04:19:59","slug":"bio-thera-solutions-expands-partnership-with-avalon-pharma-exclusive-mena-licensing-deal-for-dupixent-biosimilar-bat2406-second-collaboration-after-bat3306","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75308","title":{"rendered":"Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 \u2013 Second Collaboration After BAT3306"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Bio-Thera Solutions, Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688177:SHA\">SHA: 688177<\/a>) and Saudi Arabia\u2011headquartered <strong>Avalon Pharma<\/strong> announced the <strong>expansion of their partnership<\/strong>, signing a new <strong>licensing agreement<\/strong> under which Avalon Pharma will secure <strong>exclusive rights to distribute and commercialize BAT2406<\/strong>, a <strong>Dupixent (dupilumab) biosimilar<\/strong>, in <strong>Saudi Arabia<\/strong> and across the <strong>Middle East and North Africa (MENA) region<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-structure\" class=\"wp-block-heading\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Deal Type<\/strong><\/td><td>Exclusive licensing \/ commercialization agreement<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>BAT2406 (biosimilar candidate referencing Sanofi&#8217;s Dupixent \/ dupilumab)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Avalon Pharma (Saudi Arabia HQ)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Saudi Arabia + other MENA markets<\/td><\/tr><tr><td><strong>Bio\u2011Thera&#8217;s Role<\/strong><\/td><td>R&amp;D, manufacturing, and commercial supply of BAT2406<\/td><\/tr><tr><td><strong>Avalon&#8217;s Role<\/strong><\/td><td>Exclusive commercialization rights across MENA<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>19 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-bat2406\" class=\"wp-block-heading\">Product Profile \u2013 BAT2406<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reference Product:<\/strong> Sanofi&#8217;s <strong>Dupixent (dupilumab)<\/strong><\/li>\n\n\n\n<li><strong>Class:<\/strong> Biosimilar candidate targeting <strong>type 2 inflammatory and related atopic\/allergic diseases<\/strong><\/li>\n\n\n\n<li><strong>Indications Under Development:<\/strong><\/li>\n\n\n\n<li>Atopic dermatitis<\/li>\n\n\n\n<li>Asthma<\/li>\n\n\n\n<li>Prurigo nodularis<\/li>\n\n\n\n<li>Chronic rhinosinusitis with nasal polyps<\/li>\n\n\n\n<li>Eosinophilic esophagitis<\/li>\n\n\n\n<li><strong>Division of Responsibilities:<\/strong> <strong>Bio\u2011Thera Solutions<\/strong> handles development, manufacturing and supply; <strong>Avalon Pharma<\/strong> executes regional commercialization.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-partnership-history-second-mena-collaboration\" class=\"wp-block-heading\">Partnership History \u2013 Second MENA Collaboration<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Collaboration<\/th><th>Product<\/th><th>Reference Drug<\/th><th>Territory<\/th><\/tr><\/thead><tbody><tr><td><strong>First Agreement<\/strong><\/td><td>BAT3306<\/td><td>MSD&#8217;s Keytruda (pembrolizumab) biosimilar<\/td><td>MENA region<\/td><\/tr><tr><td><strong>New Agreement<\/strong><\/td><td>BAT2406<\/td><td>Sanofi&#8217;s Dupixent (dupilumab) biosimilar<\/td><td>Saudi Arabia + MENA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This marks the <strong>second collaboration<\/strong> between the two companies, building on the prior BAT3306 (pembrolizumab biosimilar) agreement for the same region and signaling a deepening strategic alliance in biosimilars.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Blockbuster Reference Market:<\/strong> Dupixent is one of the world&#8217;s top\u2011selling immunology drugs, making a dupilumab biosimilar a high\u2011value asset as exclusivity cliffs approach.<\/li>\n\n\n\n<li><strong>MENA Growth Opportunity:<\/strong> Saudi Arabia and the broader MENA region represent an expanding biologics market where local commercial partners like <strong>Avalon Pharma<\/strong> provide regulatory navigation and market access.<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> With both <strong>BAT3306<\/strong> (Keytruda biosimilar) and <strong>BAT2406<\/strong> (Dupixent biosimilar) in the same regional partnership, the alliance now spans oncology and immunology franchises.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> Regulatory submissions for BAT2406 in MENA markets, development milestones, and potential further expansion of the Bio\u2011Thera \u00d7 Avalon partnership to additional assets or territories.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development, regulatory approvals, and commercial expectations for BAT2406. Actual results may differ due to risks including regulatory decisions, manufacturing and supply execution, and competitive dynamics in the MENA region.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bio-Thera Solutions, Ltd. (SHA: 688177) and Saudi Arabia\u2011headquartered Avalon Pharma announced the expansion of their&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4592,289,43,1055],"class_list":["post-75308","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-avalon-pharma","tag-bio-thera-solutions","tag-biosimilars","tag-sha-688177"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 \u2013 Second Collaboration After BAT3306 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bio-Thera Solutions, Ltd. (SHA: 688177) and Saudi Arabia\u2011headquartered Avalon Pharma announced the expansion of their partnership, signing a new licensing agreement under which Avalon Pharma will secure exclusive rights to distribute and commercialize BAT2406, a Dupixent (dupilumab) biosimilar, in Saudi Arabia and across the Middle East and North Africa (MENA) region.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75308\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 \u2013 Second Collaboration After BAT3306\" \/>\n<meta property=\"og:description\" content=\"Bio-Thera Solutions, Ltd. (SHA: 688177) and Saudi Arabia\u2011headquartered Avalon Pharma announced the expansion of their partnership, signing a new licensing agreement under which Avalon Pharma will secure exclusive rights to distribute and commercialize BAT2406, a Dupixent (dupilumab) biosimilar, in Saudi Arabia and across the Middle East and North Africa (MENA) region.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75308\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-19T04:19:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-19T04:19:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75308#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75308\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 \u2013 Second Collaboration After BAT3306\",\"datePublished\":\"2026-08-19T04:19:58+00:00\",\"dateModified\":\"2026-08-19T04:19:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75308\"},\"wordCount\":387,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Avalon Pharma\",\"Bio-Thera Solutions\",\"Biosimilars\",\"SHA: 688177\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75308#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75308\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75308\",\"name\":\"Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 \u2013 Second Collaboration After BAT3306 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-19T04:19:58+00:00\",\"dateModified\":\"2026-08-19T04:19:59+00:00\",\"description\":\"Bio-Thera Solutions, Ltd. (SHA: 688177) and Saudi Arabia\u2011headquartered Avalon Pharma announced the expansion of their partnership, signing a new licensing agreement under which Avalon Pharma will secure exclusive rights to distribute and commercialize BAT2406, a Dupixent (dupilumab) biosimilar, in Saudi Arabia and across the Middle East and North Africa (MENA) region.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75308#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75308\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75308#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 \u2013 Second Collaboration After BAT3306\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 \u2013 Second Collaboration After BAT3306 - Insight, China&#039;s Pharmaceutical Industry","description":"Bio-Thera Solutions, Ltd. (SHA: 688177) and Saudi Arabia\u2011headquartered Avalon Pharma announced the expansion of their partnership, signing a new licensing agreement under which Avalon Pharma will secure exclusive rights to distribute and commercialize BAT2406, a Dupixent (dupilumab) biosimilar, in Saudi Arabia and across the Middle East and North Africa (MENA) region.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75308","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 \u2013 Second Collaboration After BAT3306","og_description":"Bio-Thera Solutions, Ltd. (SHA: 688177) and Saudi Arabia\u2011headquartered Avalon Pharma announced the expansion of their partnership, signing a new licensing agreement under which Avalon Pharma will secure exclusive rights to distribute and commercialize BAT2406, a Dupixent (dupilumab) biosimilar, in Saudi Arabia and across the Middle East and North Africa (MENA) region.","og_url":"https:\/\/flcube.com\/?p=75308","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-19T04:19:58+00:00","article_modified_time":"2026-08-19T04:19:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75308#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75308"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 \u2013 Second Collaboration After BAT3306","datePublished":"2026-08-19T04:19:58+00:00","dateModified":"2026-08-19T04:19:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75308"},"wordCount":387,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Avalon Pharma","Bio-Thera Solutions","Biosimilars","SHA: 688177"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75308#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75308","url":"https:\/\/flcube.com\/?p=75308","name":"Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 \u2013 Second Collaboration After BAT3306 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-19T04:19:58+00:00","dateModified":"2026-08-19T04:19:59+00:00","description":"Bio-Thera Solutions, Ltd. (SHA: 688177) and Saudi Arabia\u2011headquartered Avalon Pharma announced the expansion of their partnership, signing a new licensing agreement under which Avalon Pharma will secure exclusive rights to distribute and commercialize BAT2406, a Dupixent (dupilumab) biosimilar, in Saudi Arabia and across the Middle East and North Africa (MENA) region.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75308#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75308"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75308#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 \u2013 Second Collaboration After BAT3306"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75308"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75308\/revisions"}],"predecessor-version":[{"id":75309,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75308\/revisions\/75309"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}